OncRef

Clinical Trial: NCT03150875

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Innovent Biologics (Suzhou) Co. Ltd.
Information Provided By:Innovent Biologics (Suzhou) Co. Ltd.
Last Update Posted:2023-02-28

Study Overview

Brief Summary

Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

Additionally, the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC patients as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed

Official Title

Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: IBI308
  • Drug: Docetaxel

Other Study ID Numbers

  • CIBI308C301

Start Date (Actual)

2017-09-01

Primary Completion Date (Actual)

2023-02-22

Study Completion Date (Actual)

2023-02-22

Enrollment (Actual)

290

Study Type

Interventional

Phase

Phase 3